Treatment - Page 4 of 470 Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Evaluating the effectiveness of decitabine combined with allogeneic hematopoietic stem cell transplantation for the treatment of patients with recurrent and refractory acute myeloid leukemia.

Evaluating the effectiveness of decitabine combined with allogeneic hematopoietic stem cell transplantation for the treatment of patients with recurrent and refractory acute myeloid leukemia.

Posted by on Jun 11, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness of decitabine (Dacogen) combined with allogeneic hematopoietic stem cell transplantation (allo-HSCT) for the treatment of patients with recurrent and refractory (r/r) acute myeloid leukemia (AML). The data showed that decitabine combined with allo-HSCT reduced the risk of recurrence and improved...

Read More

Evaluating the effectiveness of progestin-primed ovarian stimulation protocol for infertile patients with different ovarian reserve functions.

Evaluating the effectiveness of progestin-primed ovarian stimulation protocol for infertile patients with different ovarian reserve functions.

Posted by on Jun 11, 2023 in Infertility | 0 comments

In a nutshell This study evaluated the effectiveness of progestin-primed ovarian stimulation (PPOS) protocol for infertile patients with different ovarian reserve functions. The data showed that PPOS is an effective ovarian stimulation protocol and is beneficial for these patients. Some background Many couples with infertility opt to use assisted...

Read More

Does transcranial direct current stimulation improve speech production in patients with speech impairment after stroke?

Does transcranial direct current stimulation improve speech production in patients with speech impairment after stroke?

Posted by on Jun 11, 2023 in Stroke | 0 comments

In a nutshell This study evaluated the effectiveness of transcranial direct current stimulation (tDCS) on speech intelligibility, and speech-related physiological and vocal functions in dysarthric (speech impairment) patients after stroke. The data showed that tDCS enhanced the effects of traditional speech therapy in these patients. Some...

Read More

Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.

Evaluating the effectiveness and safety of pembrolizumab for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma before stem cell transplantation.

Posted by on Jun 11, 2023 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of pembrolizumab (Keytruda) for the treatment of patients with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL) before stem cell transplantation. The data showed that pembrolizumab was effective and safe with manageable side effects in these patients. Some background...

Read More

Evaluating the effectiveness of chemotherapy for patients with resectable colorectal cancer liver metastases.

Evaluating the effectiveness of chemotherapy for patients with resectable colorectal cancer liver metastases.

Posted by on Jun 11, 2023 in Colorectal cancer | 0 comments

In a nutshell This study evaluated the effectiveness of chemotherapy before surgery for the treatment of patients with resectable colorectal cancer liver metastasis (CRLM). The data showed that the addition of chemotherapy before surgery significantly improved disease-free survival (survival without any signs or symptoms of cancer) but not the...

Read More

Evaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of olaparib with or without cediranib in patients with metastatic castration-resistant prostate cancer.

Posted by on Jun 11, 2023 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of olaparib (Lynparza) with or without cediranib (Recentin) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that cediranib combined with olaparib significantly improved survival without cancer worsening compared with olaparib alone in these patients....

Read More

Evaluating the long-term outcomes of nivolumab plus ipilimumab versus chemotherapy as first-line treatment for advanced non-small cell lung cancer.

Evaluating the long-term outcomes of nivolumab plus ipilimumab versus chemotherapy as first-line treatment for advanced non-small cell lung cancer.

Posted by on Jun 11, 2023 in Lung cancer | 0 comments

In a nutshell This evaluated the long-term outcomes of nivolumab (Opdivo) plus ipilimumab (Yervoy) versus chemotherapy as first-line treatment for advanced non-small cell lung cancer (NSCLC). The data showed that nivolumab plus ipilimumab increased the long-term overall survival versus chemotherapy in these patients. Some background NSCLC is the most...

Read More

Comparing the long-term effectiveness of accelerated partial breast irradiation using multicatheter brachytherapy with whole-breast irradiation in patients with early breast cancer

Comparing the long-term effectiveness of accelerated partial breast irradiation using multicatheter brachytherapy with whole-breast irradiation in patients with early breast cancer

Posted by on May 28, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the long-term effectiveness of accelerated partial breast irradiation (ABPI) using multicatheter brachytherapy (BT) with whole-breast irradiation (WBI) in patients with early breast cancer (BC). The study found that ABPI using multicatheter BT was similarly effective with fewer serious side effects compared to...

Read More

Can the use of with tofacitinib or tumor necrosis factor inhibitors (TNFi) affect the risk of cancer development in patients with rheumatoid arthritis?

Can the use of with tofacitinib or tumor necrosis factor inhibitors (TNFi) affect the risk of cancer development in patients with rheumatoid arthritis?

Posted by on May 28, 2023 in Rheumatoid Arthritis | 0 comments

In a nutshell This study investigated the occurrence and baseline risk factors of cancer occurrence in patients with rheumatoid arthritis (RA) treated with tofacitinib (Xeljanz) or tumor necrosis factor inhibitors (TNFis). The data showed a higher risk of cancer development with tofacitinib treatment compared to TNFis in these patients.  Some...

Read More

Can oral azacitidine maintenance promote longer survival in older patients with acute myeloid leukemia in first remission following chemotherapy?

Can oral azacitidine maintenance promote longer survival in older patients with acute myeloid leukemia in first remission following chemotherapy?

Posted by on May 28, 2023 in Leukemia | 0 comments

In a nutshell This study evaluated the effectiveness of oral azacitidine (Onureg; Oral-AZA) maintenance treatment in older patients with acute myeloid leukemia (AML) in remission. The data showed that Oral-AZA maintenance therapy can be considered in older patients with AML for which hematopoietic stem cell transplantation (HSCT) is not an...

Read More

Evaluating the effectiveness of magnetic stimulation in female urgency urinary incontinence

Evaluating the effectiveness of magnetic stimulation in female urgency urinary incontinence

Posted by on May 25, 2023 in Urinary incontinence | 0 comments

In a nutshell The study evaluated the effectiveness of magnetic stimulation (MS) in urgency urinary incontinence (UUI). The study found that MS showed promising results in treating UUI. Some background Urinary incontinence (UI) is the involuntary leakage of urine. Urinary incontinence is categorized into stress UI, urgency UI, and mixed UI. UUI is a...

Read More

Evaluating the effectiveness and safety of TAC-302 in patients with detrusor underactivity and overactive bladder.

Evaluating the effectiveness and safety of TAC-302 in patients with detrusor underactivity and overactive bladder.

Posted by on May 24, 2023 in Overactive bladder | 0 comments

In a nutshell This study evaluated the effectiveness and safety of TAC-302 in patients with detrusor underactivity (DU) and overactive bladder (OAB). The study found that TAC-302 may benefit patients with DU. Some background Overactive bladder (OAB) occurs when the bladder muscle is too active. Instead of staying at rest as urine fills the bladder,...

Read More